(MedPage Today) — The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
The tablets are indicated…
Source link : https://www.medpagetoday.com/nephrology/generalnephrology/114955
Author :
Publish date : 2025-04-03 16:51:00
Copyright for syndicated content belongs to the linked Source.
